3月10日，天演药业(ADAG)盘中上涨2.96%，截至22:38，报2.09美元/股，成交480.0美元，总市值9252.59万美元。
财务数据显示，截至2023年12月31日，天演药业收入总额1811.15万美元，同比增长94.9%；归母净利润-1894.64万美元，同比增长76.31%。
大事提醒：
7月22日，天演药业获HC Wainwright重申评级Buy，目标价5美元。
资料显示，天演药业公司(纳斯达克股票代码:ADAG)是平台驱动并拥有自主平台产出的临床产品开发阶段的生物制药公司,公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。借助计算生物学和人工智能相结合的强大平台,公司研制出高安全性和有效性的新型抗体,为更多癌症患者带来了福音。公司的抗体发现引擎——“动态精准抗体库”(Dynamic Precision Library),正在推动天演药业的产品管线开发,致力于打造潜在的全球创新或同类最佳型产品。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.